Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura

Area of Science:

• Neurology
• Pharmacology

Background:

• Botulinum toxin type-A has shown promise for migraine prophylaxis in open-label studies.
• Placebo-controlled trial data for botulinum toxin type-A in migraine has been conflicting.

Purpose of the Study:

• To assess the efficacy, safety, and optimal dosage of Clostridium botulinum type A toxin-hemagglutinin complex (Dysport) for preventing migraines.
• To compare Dysport at 120 and 240 units against a placebo in a double-blind, randomized trial.

Main Methods:

• A 12-week, double-blind, randomized trial involving 128 patients with migraine without aura.
• Primary endpoint: change in mean migraine attacks per 4-week period.
• Secondary endpoints: headache intensity, duration, disability, and quality of life scores.

Main Results:

• No significant difference in the primary endpoint (migraine attack frequency) between Dysport and placebo.
• Dysport-240 showed significant reduction in headache duration and intensity during weeks 0-4.
• Significant improvements in patient and investigator global assessments were observed with Dysport-240.

Conclusions:

• Study design limitations may have impacted primary endpoint results.
• Dysport-240 demonstrated some significant benefits over placebo, particularly in early-phase outcomes.
• Further research with refined outcome measures is necessary to fully evaluate Dysport for migraine prophylaxis.